InVivo Therapeutics Corporation (NVIV) Appoints Christopher McNulty As Vice President, Business Development & Investor Relations

InVivo Therapeutics Holdings Corp. (NVIV) today announced that the role of Christopher McNulty has been expanded to include investor relations and corporate communications. Mr. McNulty has been serving as Vice President, Business Development, and will continue to lead efforts in that area. 

Suggested Articles

Former Ipsen and Novartis exec Harout Semerjian has been tapped as the latest chief executive of troubled Immunomedics.

A COVID-19 vaccine developed by a Mass General spinoff is among the candidates emerging from partnerships between tech developers and bio researchers.

Vir and GlaxoSmithKline will pool their resources to develop vaccines and treatments for coronaviruses, starting with two antibodies against COVID-19.